How is the clinical implication of high expression of miR-181a in acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Schwind et al measured miR-181a expression in pretreatment marrows in 187 adults (< 60 y) with CN-AML. Higher miR-181a expression was associated with a higher complete remission (CR) rate (P =0.04), longer OS (P =0.01) and a trend for longer disease-free survival (P =0.09). The impact of miR-181a was most striking in poor molecular risk patients with FLT3-ITD and/or NPM1 wild-type, where higher miR-181a expression was associated with a higher CR rate (P =0.009) and longer disease-free survival (P<0.001) and OS (P<0.001). In multivariable analyses, higher miR-181a expression was significantly associated with better outcome, both in the whole patient cohort and in patients with FLT3-ITD and/or NPM1 wild-type. These results were also validated in an independent set of older (≥60 y) patients with CN-AML. [36]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!